tiprankstipranks
Immix Biopharma, Inc. (IMMX)
NASDAQ:IMMX
US Market
IMMX
Immix Biopharma
RESEARCH TOOLSreports

Immix Biopharma (IMMX) Price & Analysis

197 Followers

IMMX Stock Chart & Stats

$10.35
-$0.03(-1.32%)
At close: 4:00 PM EST
$10.35
-$0.03(-1.32%)
Day’s Range― - ―
52-Week Range$1.94 - $11.61
Previous Close$2.25
Volume74.23K
Average Volume (3M)1.60M
Market Cap
$710.48M
Enterprise Value$418.48M
Total Cash (Recent Filing)$90.58M
Total Debt (Recent Filing)$1.04M
Price to Earnings (P/E)―
Beta1.23
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding71,189,950
10 Day Avg. Volume1,994,854
30 Day Avg. Volume1,599,227
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)1.84
Price to Sales (P/S)0.00
P/FCF Ratio-6.99
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.20K
Enterprise Value/Ebitda-12.11
Forecast
1Y Price Target
$20.25
Price Target Upside95.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.69
Revenue Forecast (FY)N/A

Immix Biopharma News

Immix Biopharma initiated with a Buy at BofA
Immix Biopharma initiated with a Buy at BofA
BofA initiated coverage of Immix Biopharma (IMMX) with a Buy rating and $27 price target Early data on...
11d ago
IMMX
Immix Biopharma initiated with an Outperform at LifeSci Capital
Immix Biopharma initiated with an Outperform at LifeSci Capital
LifeSci Capital initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $19 price target Published first...
12d ago
IMMX
Immix Biopharma Shareholders Back Board and Auditor at AGM
Immix Biopharma Shareholders Back Board and Auditor at AGM
The latest update is out from Immix Biopharma ( ($IMMX) ). At Immix Biopharma’s 2026 Annual Meeting of...
1M ago
8K
IMMX
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Immix Biopharma (IMMX) to $20 from $15...
1M ago
IMMX
Immix Biopharma Raises $150 Million to Advance NXC-201
Immix Biopharma Raises $150 Million to Advance NXC-201
The latest announcement is out from Immix Biopharma ( ($IMMX) ). On May 21, 2026, Immix Biopharma priced...
1M ago
8K
IMMX
Immix Biopharma Reports Strong Interim NXC-201 Phase 2 Data
Immix Biopharma Reports Strong Interim NXC-201 Phase 2 Data
An announcement from Immix Biopharma ( ($IMMX) ) is now available. On May 21, 2026, Immix Biopharma reported...
1M ago
8K
IMMX
Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis
Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis
Immix Biopharma (IMMX) announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted...
1M ago
IMMX
Citizens biotechnology analyst holds analyst/industry conference call
Citizens biotechnology analyst holds analyst/industry conference call
Biotech Analysts discuss AL Amyloidosis and the potential of NXC-201 (relevant companies IMMX, REGN, ABBV, AZ, JNJ, GSK...
3M ago
AZ
GSK
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201
Immix Biopharma ( ($IMMX) ) has shared an announcement. On March 30, 2026, Immix Biopharma announced it had...
3M ago
8K
IMMX
Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3,...
3M ago
MRK
IMMX
Immix Biopharma price target raised to $15 from $14 at Mizuho
Immix Biopharma price target raised to $15 from $14 at Mizuho
Mizuho raised the firm’s price target on Immix Biopharma (IMMX) to $15 from $14 and keeps an Outperform...
3M ago
IMMX
Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright
Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $15 from $12 and keeps a...
3M ago
IMMX
Immix Biopharma Amends ATM Offering to Raise Capital
Immix Biopharma Amends ATM Offering to Raise Capital
An update from Immix Biopharma ( ($IMMX) ) is now available. On March 25, 2026, Immix Biopharma amended...
3M ago
8K
IMMX
Immix Biopharma initiated with an Overweight at Morgan Stanley
Immix Biopharma initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Immix Biopharma (IMMX) with an Overweight rating and $20 price target The company...
3M ago
IMMX

IMMX FAQ

What was Immix Biopharma, Inc.’s price range in the past 12 months?
Immix Biopharma, Inc. lowest stock price was $1.94 and its highest was $11.61 in the past 12 months.
    What is Immix Biopharma, Inc.’s market cap?
    Immix Biopharma, Inc.’s market cap is $710.48M.
      When is Immix Biopharma, Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Immix Biopharma, Inc.’s earnings last quarter?
      Currently, no data Available
      Is Immix Biopharma, Inc. overvalued?
      According to Wall Street analysts Immix Biopharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Immix Biopharma, Inc. pay dividends?
        Immix Biopharma, Inc. does not currently pay dividends.
        What is Immix Biopharma, Inc.’s EPS estimate?
        Immix Biopharma, Inc.’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Immix Biopharma, Inc. have?
        Immix Biopharma, Inc. has 71,189,950 shares outstanding.
          What happened to Immix Biopharma, Inc.’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Immix Biopharma, Inc.?
          Currently, no hedge funds are holding shares in IMMX
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Immix Biopharma Stock Smart Score

            6
            Neutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Analyst Consensus

            Strong Buy
            Average Price Target:
            $20.25 (95.65% Upside)

            Blogger Sentiment

            Bullish
            IMMX Sentiment 70%
            Sector Average ―

            Hedge Fund Trend

            Decreased
            By 327.6K Shares
            Last Quarter.

            Crowd Wisdom

            Very Positive
            Last 7 Days ▲ 1.5%
            Last 30 Days ▲ 9.3%

            Technicals

            SMA
            Positive
            20 days / 200 days
            Momentum
            345.53%
            12-Months-Change

            Fundamentals

            Return on Equity
            -73.23%
            Trailing 12-Months
            Asset Growth
            381.68%
            Trailing 12-Months
            Top Smart Score Stocks >

            Company Description

            Immix Biopharma, Inc.

            Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.

            IMMX Stock 12 Month Forecast

            Average Price Target

            $20.25
            ▲(95.65% Upside)
            {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","28":"$28","7.75":"$7.75","14.5":"$14.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$27.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.75,14.5,21.25,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,10.587692307692308,11.955384615384617,13.323076923076924,14.69076923076923,16.05846153846154,17.426153846153845,18.793846153846154,20.161538461538463,21.52923076923077,22.89692307692308,24.264615384615386,25.63230769230769,{"y":27,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,10.06846153846154,10.916923076923077,11.765384615384615,12.613846153846154,13.462307692307693,14.310769230769232,15.159230769230769,16.00769230769231,16.856153846153845,17.704615384615387,18.553076923076922,19.40153846153846,{"y":20.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.22,9.664615384615384,10.10923076923077,10.553846153846154,10.99846153846154,11.443076923076923,11.887692307692308,12.332307692307692,12.776923076923078,13.221538461538461,13.666153846153847,14.11076923076923,14.555384615384614,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.23,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
            Detailed Analyst Forecast >

            Technical Analysis

            Overall Consensus
            Buy
            14Bullish
            5Neutral
            3Bearish
            Bullish
            Neutral
            Bearish
            Overall Consensus
            14
            5
            3
            Technical Analysis
            2
            5
            3
            Moving Averages
            12
            0
            0
            Technical Analysis >
            Similar Stocks
            Company
            Price & Change
            Follow
            ATHE
            Alterity Therapeutics
            ―
            ―
            VTGN
            VistaGen Therapeutics
            ―
            ―
            ―
            ―
            ―
            HYFT
            MindWalk Holdings
            ―
            ―
            INKT
            MiNK Therapeutics
            ―
            ―
            Compare IMMX Stocks >

            Ownership Overview

            17.21%7.67%17.11%52.02%
            17.21% Insiders
            7.67% Mutual Funds
            17.11% Other Institutional Investors
            52.02% Public Companies and
            Individual Investors
            Detailed Ownership Overview >

            Options Prices

            Detailed Option Prices >
            Popular Stocks